Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.54 |
| ▸ | CNR2 | P34972 | 6/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 2/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637141 | 0.83 | MAPK14 (0.54) | MAPK14CNR2MAPK13MAPK12MAPK11 | |
| SCHEMBL13315081 | 0.79 | MAPK14 (0.56) | MAPK14CNR2MAPK13MAPK12MAPK11 | |
| SCHEMBL3549246 | 0.71 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3551910 | 0.71 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11LMNA | |
| SCHEMBL3541919 | 0.68 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL14459897 | 0.67 | MAPK14 (0.56) | MAPK14CNR2MAPK13MAPK12MAPK11 | |
| SCHEMBL13487559 | 0.62 | MAPK14 (0.53) | MAPK14CNR2MAPK13MAPK12MAPK11 | |
| SCHEMBL27607371 | 0.62 | ALDH1A1 (0.46) | CNR2KDM4ERAB9ALMNA | |
| SCHEMBL2609439 | 0.62 | GRN (0.52) | MAPK14CNR2MAPK13MAPK12MAPK11 | |
| SCHEMBL13315072 | 0.61 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7612200-B2 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | LOCUS PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192307-A1 | INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K19 | MAPK14 300/4885CNR2 2502/4885MAPK13 418/4885 |
| US-20070185098-A1 | Inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K19 | MAPK14 300/4885CNR2 2502/4885MAPK13 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.